AstraZeneca Signs a Worldwide Development and Distribution Agreement with Oxford University for Vaccine Against COVID-19

 AstraZeneca Signs a Worldwide Development and Distribution Agreement with Oxford University for Vaccine Against COVID-19

AstraZeneca Signs a Worldwide Development and Distribution Agreement with Oxford University for Vaccine Against COVID-19

Shots:

  • The collaboration will bring Oxford’s recombinant adenovirus vaccine, ChAdOx1 nCoV-19 to the patients and will enable AstraZeneca to be responsible for the development and WW manufacturing and distribution of the vaccine
  • The alliance will combine Oxford’s expertise in vaccinology and AstraZeneca’s global development, manufacturing and distribution capabilities to combat the pandemic
  • ChAdOx1 is based on adenoviral vector technology and has entered P-I clinical study last week to evaluate its safety and efficacy in healthy volunteers aged 18-55yrs., across five centers in Southern England with its anticipated results in next month and the expected advancement to late-stage studies by the middle of the year

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: Sky News

Related News: Oxford Biomedica Joins Consortium to Develop ChAdOx1 nCov-19 for COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post